A patient with typical Philadelphia chromosome (Ph')-positive chronic myelocytic leukemia (CML) was studied during sequential phases of disease: (1) initial chronic phase; (2) myeloid blast crisis; (3) second chronic phase; and (4) accelerated disease. A point mutation in the coding sequence of the p53 gene first appeared concomitantly with the blast crisis and then disappeared with the re-establishment of a FTER A chronic phase of variable duration, chronic
FTER A chronic phase of variable duration, chronic A myelocytic leukemia (CML) usually evolves into a more aggressive clinical disease with poorly differentiated myeloid or lymphoid blast cells populating the hematopoietic tissues.' The Ph' chromosomal anomaly involving translocation of the c-ABL proto-oncogene from chromosome 9 to the bcr region of chromosome 22 is the pathogenetic molecular lesion in the chronic phase of but the lesions responsible for evolution to the blast crisis phase of disease have not been definitely identified. Mutations in the first exon of the N-RAS oncogene are found in some acute-phase cell populations and are probably responsible for CML evolution in a small minority of Recently, we and others observed deletions, rearrangements, and mutations of the p53 gene in blast crisis cases, and cell
The p53 gene is a cancer suppressor gene or "anti-oncogene."" The exact frequency of alterations of the p53 gene is unknown, but probably exceeds 30%, suggesting that abnormalities of this anti-oncogene may frequently be responsible for clonal evolution of CML. A role for p53 as the molecular culprit in blastic crisis could more convincingly be argued if changes in the gene and in clinical disease were concomitant events. Therefore, we obtained cells, over a period of 2 years, from a patient whose disease went from chronic phase to blast crisis and then returned to chronic phase after intensive chemotherapy. The p53 gene in these cells was analyzed by complete sequencing of the coding exons. The results demonstrate that development of blast crisis and p53 gene alterations are linked events in some cases of blast crisis.
MATERIALS AND METHODS
Peripheral blood leukocytes andlor bone marrow mononuclear cells were separated and stored frozen after obtaining informed consent from the patient. DNA was isolated and the p53 gene analyzed by Southern blotting and sequencing.' The sequence of bases in the coding exons 2 through 11 and most of the intronlexon junctions of the p53 gene were determined after amplification by the polymerase chain reaction (PCR) using appropriate 5 ' and 3' primers under conditions previously described.* Multiple PCR reactions were performed on each sample to exclude the possibility of amplification-induced artifacts in base sequences. Conventional methods were used for routine hematologic and karyotypic analysis.
CASE REPORT AND RESULTS
A 34-year-old man was admitted to the hospital in February 1984 with a 6-week history of fatigue and night sweats. A diagnosis of CML was made on the basis of splenomegaly, typical blood and bone marrow abnormalities, and the presence of the Ph' chromosome. The disease remained in chronic phase for almost 6 years, requiring initial treatment with busulfan and subsequently with hydroxyurea or phenylalanine mustard. In January 1990, fatigue, fever, massive splenomegaly, and a rising blast count were noted, and a diagnosis of blast crisis was made (Table 1) . Morphology and analysis with a panel of monoclonal antibodies including MY7, MY4, LM9, and anti-Tdt were consistent with a myeloid phenotype of the blastic clone.
Treatment with cytosine arabinoside, tetrahydrouridine, and carboplatin was associated with return to a second chronic phase in late February/early March 1990, and this phase persisted under treatment with mitoxantrone until May 1990, when disease began to accelerate again with rising white counts in the blood, and 14% and 19% blasts in the blood and marrow, respectively (Table 1) . A clear-cut blast crisis did not evolve at this time, but treatment with mitoxantrone and high-dose cytosine arabinoside was associated with the establishment of a brief third chronic phase in June 1990. The patient died of Escherichia coli sepsis in late July 1990, with disease again in early blastic transformation.
A blood sample obtained in September 1988, during the chronic phase of disease, showed a bcr gene rearrangement, a 46 XY Ph' karyotype, a heterozygous state for the Bgl I1 polymorphism of the p53 gene9 (Fig 1, lane A) , and a normal nucleotide sequence of the coding exons of the p53 gene (Table 1, Fig 2, lane A) . The relevant codons of exon 7 are shown in Fig 2A. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S,C. section 1734 solely to indicate this fact.
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Blood, Vol77, No 11 (June l), 1991: pp2441-2444 In January 1990, when the disease was in early myeloid blast crisis, karyotype analysis for the first time showed a new and complex profile including persistence of the original Ph'-positive clone in 33% of the metaphases and the appearance of a cellular population comprising about 60% of dividing cells with abnormalities of chromosomes X, 7, 11, 16, and a deletion of 17p as well as the Phl chromosome. It should be noted that the p53 gene resides on 17p. Southern analysis showed a loss of heterozygosity for the p53 locus (Fig 1, lane B) p53 gene had been replaced by an AGC (Fig 2B) , resulting in a change of asparagine to serine in the p53 protein.
The much higher intensity of the mutant G relative to the normal A bands (Fig 2B) suggests that the malignant blasts had a single mutant allele of the p53 gene and that the faint A band results from the persistence of antecedent chronicphase cells. Although other interpretations are possible, the pattern clearly shows that the mutant p53 allele was the dominant species in the blood in this blastic phase. A second chronic phase was induced with multiagent chemotherapy. At this time, when there were 19 x 1 0 ' white blood cells/L and less than 5% blasts in the peripheral blood, the karyotype analysis showed a 46XY pattern with the classical t(9q;22q) of the Phl chromosome in one half of the dividing cells and an additional translocation involving chromosomes 7 and X in the remaining dividing cells. The 17p deletion was no longer detectable. Analysis of the complete coding sequence of p53 once again showed a normal pattern, indicating that the predominant clone during this second chronic phase had a normally coding p53 gene. The relevant area of codon 7 is shown in Fig 2C and demonstrates disappearance of the mutant G and return of the normal A at codon 239.
In May 1990, when disease was once again accelerating, a blood sample was obtained that contained 14% blast cells. Detailed sequencing of all coding exons showed a normal p53 gene structure at this time and Fig 2D shows the relevant area of exon 7; however, it should be noted that had a rcarrangcd hcr gcnc whosc gross structurc was unchangcd throughout this pcriod. Similarly. cclls from all phascs of discasc wcrc studicd for altcrations o f cxon 1 of N-RAY, and no ahnormalitics wcrc found, indicating that activation o f this gcnc by thc common codon 13 mutation sccn in many Icukcmiash was not associatcd with changc in discasc status.
DISCUSSION
A paticnt with CML whosc discasc wcnt into mycloid blast crisis and thcn rcturncd to chronic phasc with thcrapy pcrmittcd us to analvzc scqucntial molccular altcrations during diffcrcnt phascs of discasc. Thc coding scqucncc of thc p53 gcnc was normal during thc initial chronic phasc of discasc, but a mutation in thc phylogcnctically conscrvcd rcgion of thc gcnc dcvclopcd concomitantly with thc cvolution to mycloid blast crisis. With rcinduction o f thc chronic phasc. only structurally normal pS3 gcnc scqucnccs wcrc again obscrvcd. Thc paticnt's discasc eccclcratcd again aftcr a fcw months. but thc pS3 gcnc structurc rcmaincd normal. Howcvcr. thc pcrccntagc of blasts during this phasc was only 14%. which is bclow thc scnsitivity of thc scqucncing analysis for dctccting a point mutation.s Thcrcforc, wc cannot dcfinitcly say that thc first blast crisis clonc did not rccur a sccond timc.
Thc pS3 gcnc is locatcd on thc short arm o f chromosomc 17. Thc protcin product o f this gcnc was first idcntificd as a conscqucncc o f its ability to bind to thc transforming protcins of ccrtain DNA tumor viruscs,'' and it was soon obscrvcd that cxprcssion of this gcnc was oftcn altcrcd in malignant ccll lincs. Whcn wc cxamincd human tumors for changcs in pS3, wc first obscrvcd a consistcnt abnormality o f this gcnc in human ostcosarcomas.'' Subscqucntly, ahnormalitics of pS3 wcrc found in a widc varicty of human tumors including colon. lung and brcast canccrs. and othcr sarcomas.Ih I'
Thc wcight of currcnt cvidcncc suggcsts that thc pS3 gcnc is an anti-oncogcnc. Whcn thc gcnc is dclctcd, disruptcd by a molccular rcarrangcmcnt, or altcrcd by a mutation in its coding scqucncc, thc rcsult is a loss of its normal tumor-supprcssivc function." Thus, changcs in thc gcnc havc gcncrally bccn associatcd with progrcssion rathcr than initiation o f tumors. In 1989 wc rcportcd that dclctions and rcarrangcmcnts of thc pS3 gcnc wcrc frcqucnt in thc blast crisis of CML, but wcrc rarc during thc chronic phasc and suggcstcd that acquircd changcs in pS3 wcrc rcsponsiblc for lcukcmic progression.' Howcvcr, this thcsis could not bc provcn without a dctailcd analysis of thc timing of molccular altcrations rclativc to clinic, d I cvcnts.
Conscqucntly. wc undcrtook thc prcscnt study. Our currcnt obscrvations on a carcfully studicd paticnt indicatc that the transition from chronic phasc to blast crisis and a rcturn to chronic phasc of CML was accompanicd by first a gain and thcn a loss of a clonc of cclls containing a structural abnormality of thc pS3 gcnc. Thc chromosomal altcrations that accompanicd thcsc changcs in molccular structurc and clinical status includcd a dclction of 17p. Bccausc thc pS3 gcnc is locatcd on thc short arm of chromosomc 17, wc infcr that a chromosomal cvcnt rcsultcd in loss of 17p scqucnccs with rctcntion of a singlc mutant allclc of pS3 in ;I clonc of cclls alrcady carrying thc Ph' chromosomc. A mutation in pS3 coding scqucnccs could havc prcccdcd or followcd thc loss of thc normal allclc with thc rcsult that only mutant pS3 protcin was produccd by thc ncw clonc of cclls. This circumstancc is known to bc associatcd with ccllular immortalization in othcr biologic systcms." Thc mutation of thc pS3 gcnc, which wc obscrvcd in our casc, was a mis-scnsc mutation in the singlc allclc of thc pS3 gcnc, which would havc altcrcd thc protcin in a rcgion known to bc a "hot spot" for mutations.''Ih Mutatcd pS3 proteins fail to function normally and may cvcn bind thc normal pS3 protcin whcn onc normal allclc is rctaincd by a tumor." Almost all of thc pS3 mutations thus far havc bccn of this mis-scnsc varicty,"'" although wc did find onc CML blast crisis ccll linc in which a mutation was not in thc coding scqucncc but rcsultcd in dcfcctivc proccssing of mRNA.'' Wc intcrprct our obscrvations on this casc, as wcll as prcvious studics." I" as indicating that pS3 gcnc altcrations accompany and arc probably rcsponsiblc for thc cvolution of many caws of mycloid blast crisis.
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